Sickle Cell Disease

Central IRB #H-39846/ NHLB #SCD-CARRE: Sickle Cell Disease & CardiovAscular Risk – Red cell Exchange Trial

Central IRB #H-40856/ Forma/Novo Nordisk #4202-HEM-301 (HIBISCUS): An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Agonist in Patients with Sickle Cell Disease (HIBISCUS)

Central IRB #H-44795/ Fulcrum #6058-SCD-101: A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects with Sickle Cell Disease (SCD)

Central IRB #pend/ Novo Nordisk #NN7535-7822 (FLORAL): An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study (pending IRB)

Central IRB #H-45056/ Agios #AG348-C-026: A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy (pending)